Saniona announces that FDA has approved the IND for NS2359 in cocaine addiction
Saniona, a leading biotech company within ion-channel research, announces today that the US Food and Drug Administration, FDA, has accepted the University of Pennsylvania Treatment Research Center’s (TRC) Investigational New Drug Application (IND) for NS2359. TRC is currently applying for public funding with the aim of conducting a Phase 2 clinical trial for NS2359 for treatment of cocaine addiction.Saniona informed on June 4, 2015, that it has granted TRC rights to perform a phase 2 clinical trial for cocaine addiction and that TRC has filed an IND based on drug substance from Saniona and